Synergistic effects of anlotinib and DDP on breast cancer: targeting the VEGF/JAK2/STAT3 axis

• Autors principals: Hongmei Zhang (Autor), Chunling Liu (Autor), Ye Jin (Autor), Zheng Wang (Autor), Yi Guan (Autor), Zhenxian Jia (Autor), Tong Cui (Autor), Zhi Zhang (Autor), Xuemei Zhang (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

BackgroundAnlotinib, a highly selective inhibitor of VEGFR2, has demonstrated significant anti-tumor effects in various cancers. However, its potential synergistic effects with DDP (cisplatin) in breast cancer (BRCA) remain to be fully elucidated. This study aims to discover the therapeutic efficacy...